ABVX:EPA
Abivax SA
€ ८०.३०
०.००%
(०.००) 1D
नोभेम्बर १०, १७:३७:३७ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Mkt. cap
६.९२ अरब
Avg. vol.
१.१२ लाख
Volume
०.००
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
Mkt. cap
६.९२ अरब
Avg. vol.
१.१२ लाख
Volume
०.००
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
News stories
From web sources and news partners
Investing.com
·
१५ घण्टा पहिले
ABIVAX at Guggenheim conference: obefazimod data lift outlook
Idéal Investisseur
·
१ दिन पहिले
Abivax shares drop 31% over three months and remain below their averages
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees९८
Founded२०१३ डिसेम्बर ४
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com